Presepsin: solving a soluble (CD14) problem in sepsis?
Presepsin—soluble CD14 (sCD14)—has attracted significant attention from several clinical research groups
recently as a prognostic biomarker in sepsis. In a recent issue of Intensive Care Medicine , Masson and colleagues
analyzed a subset of data from the ALBIOS trial to explore the potential of sCD14 as a biomarker in sepsis.
In this ALBIOS sub-study, these authors examined the prognostic significance of sCD14 measured at
enrollment and on days 2 and 7 in 997 critically ill patients with sepsis, adding to a burgeoning body of
published studies examining the relationship between sCD14 and the presence or severity of sepsis.
recently as a prognostic biomarker in sepsis. In a recent issue of Intensive Care Medicine , Masson and colleagues
analyzed a subset of data from the ALBIOS trial to explore the potential of sCD14 as a biomarker in sepsis.
In this ALBIOS sub-study, these authors examined the prognostic significance of sCD14 measured at
enrollment and on days 2 and 7 in 997 critically ill patients with sepsis, adding to a burgeoning body of
published studies examining the relationship between sCD14 and the presence or severity of sepsis.